NASDAQ:AEZS - AEterna Zentaris Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AEterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.95 +0.01 (+1.06 %) (As of 02/25/2020 01:08 PM ET) Add Compare Today's Range$0.94Now: $0.95▼$0.9650-Day Range$0.92MA: $1.12▼$1.4452-Week Range$0.76Now: $0.95▼$5.57Volume1,591 shsAverage Volume274,668 shsMarket Capitalization$19.03 millionP/E RatioN/ADividend YieldN/ABeta1.17 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AEZS Previous Symbol CUSIPN/A CIK1113423 Webhttp://www.aezsinc.com/ Phone843-900-3201Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$26.90 million Price / Sales0.71 Cash Flow$0.21 per share Price / Cash Flow4.46 Book Value$0.12 per share Price / Book7.92Profitability EPS (Most Recent Fiscal Year)$0.25 Net Income$4.19 million Net Margins-529.57% Return on Equity-1,428.66% Return on Assets-33.77%Miscellaneous EmployeesN/A Outstanding Shares20,032,000Market Cap$19.03 million Next Earnings Date3/24/2020 (Estimated) OptionableOptionable Receive AEZS News and Ratings via Email Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AEZS Rates by TradingView AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions What is AEterna Zentaris' stock symbol? AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS." How were AEterna Zentaris' earnings last quarter? AEterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.15. The biopharmaceutical company had revenue of $0.28 million for the quarter, compared to analysts' expectations of $0.24 million. AEterna Zentaris had a negative net margin of 529.57% and a negative return on equity of 1,428.66%. View AEterna Zentaris' Earnings History. When is AEterna Zentaris' next earnings date? AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for AEterna Zentaris. What is the consensus analysts' recommendation for AEterna Zentaris? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AEterna Zentaris in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AEterna Zentaris. What are Wall Street analysts saying about AEterna Zentaris stock? Here are some recent quotes from research analysts about AEterna Zentaris stock: 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (11/5/2019) 2. HC Wainwright analysts commented, "We maintain our Buy rating of AEZS and our 12-month price target of $5.50 per share. We derive our price target using a risk- adjusted net present value analysis of potential US and EU royalties, discounted at 18%, to reach a total rNPV of $66M for the royalty streams." (8/15/2019) Has AEterna Zentaris been receiving favorable news coverage? Media coverage about AEZS stock has been trending somewhat negative this week, InfoTrie reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AEterna Zentaris earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for AEterna Zentaris. Are investors shorting AEterna Zentaris? AEterna Zentaris saw a decrease in short interest in January. As of January 31st, there was short interest totalling 351,000 shares, a decrease of 5.8% from the January 15th total of 372,800 shares. Based on an average daily volume of 163,400 shares, the days-to-cover ratio is presently 2.1 days. Approximately 2.1% of the company's shares are sold short. View AEterna Zentaris' Current Options Chain. Who are some of AEterna Zentaris' key competitors? Some companies that are related to AEterna Zentaris include Elite Pharmaceuticals (ELTP), Stealth BioTherapeutics (MITO), Onconova Therapeutics (ONTX), Eyenovia (EYEN), Chembio Diagnostics (CEMI), Trevena (TRVN), Cumberland Pharmaceuticals (CPIX), CTI BioPharma (CTIC), Aridis Pharmaceuticals (ARDS), Entasis Therapeutics (ETTX), DiaMedica Therapeutics (DMAC), CNS Pharmaceuticals (CNSP), Q BioMed (QBIO), Catabasis Pharmaceuticals (CATB) and Leap Therapeutics (LPTX). What other stocks do shareholders of AEterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some companies that other AEterna Zentaris investors own include Repros Therapeutics (RPRX), Bausch Health Companies (BHC), DarioHealth (DRIO), EXACT Sciences (EXAS), Twitter (TWTR), Energy Transfer LP Unit (ET), AEterna Zentaris (AEZ), NovaBay Pharmaceuticals (NBY), MannKind (MNKD) and Vascular Biogenics (VBLT). Who are AEterna Zentaris' key executives? AEterna Zentaris' management team includes the folowing people: Mr. Michael V. Ward, Pres & CEO (Age 62)Ms. Leslie Auld, Sr. VP & CFOMr. Brian Garrison, Sr. VP of Global Corp. Operations & Corp. Devel.Dr. Nicola Ammer, Chief Medical Officer & VP of Clinical Devel.Mr. Olaf Althaus, GM & MD Who are AEterna Zentaris' major shareholders? AEterna Zentaris' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ikarian Capital LLC (0.59%) and Renaissance Technologies LLC (0.25%). Which major investors are selling AEterna Zentaris stock? AEZS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Which major investors are buying AEterna Zentaris stock? AEZS stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC. How do I buy shares of AEterna Zentaris? Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is AEterna Zentaris' stock price today? One share of AEZS stock can currently be purchased for approximately $0.95. How big of a company is AEterna Zentaris? AEterna Zentaris has a market capitalization of $19.03 million and generates $26.90 million in revenue each year. The biopharmaceutical company earns $4.19 million in net income (profit) each year or $0.25 on an earnings per share basis. View Additional Information About AEterna Zentaris. What is AEterna Zentaris' official website? The official website for AEterna Zentaris is http://www.aezsinc.com/. How can I contact AEterna Zentaris? AEterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 843-900-3201 or via email at [email protected] MarketBeat Community Rating for AEterna Zentaris (NASDAQ AEZS)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 403 (Vote Outperform)Underperform Votes: 295 (Vote Underperform)Total Votes: 698MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/25/2020 by MarketBeat.com StaffFeatured Article: What does cost of debt say about a company’s financial health?
